Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

alloantigen-specific allogeneic type 1 regulatory T cells T-allo10

A preparation of allogeneic CD4+ cells that were ex vivo stimulated with alloantigens, which involves exposing the cells to host antigen-presenting cells (APCs), in the presence of the immunomodulatory cytokine interleukin-10 (IL-10), with potential to prevent graft-versus-host disease (GvHD). The stimulation of the CD4+ cells by exposure to alloantigens plus IL-10 induces the differentiation of alloantigen-specific type 1 T regulatory (TR1) cells, which are hyporesponsive to the alloantigens. Upon infusion of T-allo10 and prior to donor hematopoietic stem cell transplantation (HSCT), the alloantigen-specific type 1 regulatory T cells are tolerant to the alloantigens and suppress alloreactive immune responses by donor CD4+ and CD8+ T cells. This may ultimately prevent GvHD. IL-10 plays a key role in controlling inflammation, down-regulating immune responses, and inducing immunological tolerance. IL-10 induces both a long lasting antigen specific T-cell anergy and the differentiation of TR1 cells.
Synonym:alloantigen-specific TR1 cells Allo10
alloantigen-specific type 1 Tregs T-allo10
donor-derived host alloantigen-specific IL-10 anergized T cells
T-allo10 cells
Abbreviation:T-allo10
Search NCI's Drug Dictionary